Abstract: Primary Sj€ ogren's syndrome (pSS) is a chronic inflammatory autoimmune illness of the moisture-producing glands such as salivary glands that is characterized by various immune abnormalities. The aetiology of pSS remains unclear and there is no curative agent. In this study, we investigated the putative therapeutic effects on a NOD/Ltj mouse model of Sj€ ogren's syndrome-like disorders of an ester derivative of paeoniflorin, paeoniflorin-6 0 O-benzene (termed CP-25). Our study showed that CP-25 alleviated effectively clinical manifestations in NOD/Ltj mice resulting, for example, in increased salivary flow and reduced histopathological scores. Furthermore, CP-25 decreased lymphocyte viability in NOD/Ltj mice and attenuated the infiltration of Th1 cells and Th2 cells into the salivary glands of NOD/Ltj mice. In the spleen on NOD/Ltj mice, CP-25 skewed the ratio of Th17 and regulatory T cells towards regulatory T cells. After treatment, concentrations of anti-La/SSB and IgG antibodies were reduced and the titre of the inflammatory cytokines IFN-c, IL-4, IL-6 and IL-17A in the serum on NOD/Ltj mice was alleviated. Thus, we define CP-25 as a novel compound that is a potent therapeutic agent for pSS by modulating T lymphocyte subsets. Future studies will validate the use of CP-25 as a therapeutic strategy for the treatment of pSS.
Primary Sj€ ogren's syndrome (pSS) is an organ-specific, chronic autoimmune inflammation that primarily affects and destroys salivary and lacrimal glands, but can involve all moisture-producing glands. It is characterized by various clinical and laboratory manifestations, such as xerostomia and xerophthalmia, focal lymphocytic infiltration of exocrine glands, hypergammaglobulinaemia and the presence of autoantibodies which display multiple specificities [1] [2] [3] . Like many other autoimmune diseases, the pathogenesis of pSS is not yet clear. Current studies have shown that hereditary, viral and environmental factors play important roles in the aetiology and pathogenesis of pSS [4, 5] . After the onset of the disease, a large number of activated T lymphocytes are present in the inflamed exocrine glands which are thought to play a key role in the progression of pSS. These immune cells have been shown to be directly involved in the destruction of the tissue and to provide a stimulus for B lymphocytes [6] . Originally, an imbalance between Th1 cells and Th2 cells had been considered to have a central role in the aetiology of autoimmune disorders including pSS [7] [8] [9] . In recent years, this hypothesis has been modified after the new paradigm of different roles for various T cell subsets such as T helper cells (Th1, Th2, Th17) and regulatory T cells (Treg) has become better defined. Studies in animal models and human beings have revealed that in particular, Th17 cells and IL-17 family cytokines and their major regulatory antagonists Tregs play vital roles in the development chronic inflammatory diseases including pSS [10] [11] [12] [13] .
A curative agent for pSS is lacking and current treatments are often utilized based on results from other autoimmune diseases [14] . Suppression of an excessive abnormal immune response is critical to attenuate the symptoms of patients with pSS, and glucocorticoids or immunosuppressive therapy is therefore frequently utilized [15, 16] . Furthermore, commonly used immunosuppressive agents include hydroxychloroquine (HCQ), rituximab, methotrexate and tumour necrosis factor inhibitors [17] . When used for treatment, these drugs also have many adverse effects, such as macular degeneration, gastrointestinal adverse effects and an increased risk of tumour development. Thus, effective and safe therapeutic agents that protect against pSS are urgently needed. The natural plant extract 'total glucosides of paeony (TGP)' which constitutes a mixture of glycosides with the monoterpene glucoside Pae as major bioactive component has been widely used for the treatment of autoimmune diseases, such as adjuvant arthritis (AA), due to its anti-inflammatory effects [18, 19] . However, the glycoside Pae is poorly absorbed via oral administration due to poor permeation, glucosidase hydrolysis and efflux via P-glycoprotein [20] [21] [22] . A new ester derivative of Pae that includes modifications, such as the addition of benzene sulphonate, and has been termed CP-25 was synthesized in our laboratory ( fig. 1) . Compared with Pae, the lipid solubility and bioavailability of CP-25 were increased significantly, which can be attributed to its resistance to P-gp-mediated efflux and enhanced lipid solubility. As a consequence, a better tissue distribution of CP-25 was achieved [23, 24] .
The mouse strain NOD/Ltj which has been derived from a cataract-prone strain of outbred Jcl/ICR mice spontaneously develops lymphocytic infiltration in the salivary and lacrimal glands beginning at 8 weeks of age, followed by secretory dysfunction at approximately 16 weeks of age. In accordance with patients with pSS, these mice also express several characteristic species of autoantibodies, including anti-SSA/Ro and anti-SSB/La [25] , and are considered to be the most appropriate experimental Sj€ ogren's syndrome (ESS) model that allows us to study pSS [26] . In this study, we treated NOD/Ltj mice with CP-25 to determine the potential therapeutic effects of CP-25 treatment in NOD/Ltj mice and identified a diseaseattenuating effect of CP-25 in ESS in NOD/Ltj mice and an associated modulation of T lymphocyte subsets. These newly identified therapeutic effects of CP-25 in NOD/Ltj mice emphasize its potential as a new drug for treating pSS.
Materials and Methods
Animals. Female NOD/Ltj mice and ICR mice weighing 18-20 g, all 8 weeks of age, were purchased from the Laboratory Animal Center in Peking University. They received food and water under specific pathogen-free conditions in the Laboratory Animal Center of Anhui Medical University. When they were 15 weeks old, the NOD/Ltj mice were subjected to treatment. All animal studies were performed in accordance with a protocol approved by the animal care group and Ethics Review Committee for Animal Experimentation of the Institute of Clinical Pharmacology, Anhui Medical University.
Reagents. Hydroxychloroquine was purchased from the Shanghai Zhongxi Pharmaceutical (Group) Co., Ltd., Shanghai, China). Pilocarpine, sodium pentobarbital, lipopolysaccharides (LPS), concanavalin A (Con A) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were all obtained from Sigma Chemical Co. (St. Louis, MO, USA). Cell counting kit-8 (CCK-8) was obtained from Dojindo Laboratories (Kumamoto, Japan). Enzyme-linked immunosorbent assay (ELISA) kits for mouse anti-SSA/Ro and anti-SSB/La antibodies were purchased from Alpha Diagnostic Intl., Inc. Grouping and administration. NOD/Ltj mice were divided into five groups and administered three different intragastric doses of CP-25 (17.5, 35 or 70 mg/kg/day) and HCQ (80 mg/kg/day) 2 weeks after they reached 15 weeks of age. CP-25 and HCQ were suspended in 0.5% sodium carboxymethylcellulose (CMC-Na) at the desired concentration before use. Mice in the normal (Jcl/ICR mice) and pSS model groups were given an equal volume of vehicle that contained 0.5% CMC-Na. All mice were killed by cervical dislocation when they were 17 weeks old.
Mouse weight and indexes for thymuses, spleens and salivary glands. The body-weight of each mouse was recorded weekly from week 13. After the mice were killed by cervical dislocation, thymuses, spleens and salivary glands were collected and weighed. Indexes for thymuses, spleens and salivary glands were calculated based on the following formulae: thymus index (mg/g) = weight of thymus (mg)/ body-weight (g); spleen index (mg/g) = weight of spleen (mg)/bodyweight (g); and salivary gland index (mg/g) = weight of salivary gland (mg)/body-weight (g).
Salivary flow. An intraperitoneal injection of 2.4% sodium pentobarbital (5 ml/kg body-weight) was given to each animal. Subsequently, the mice were injected intraperitoneally with pilocarpine (0.125 mg/kg body-weight). Five minutes later, saliva was collected for 10 min. using a dry cotton ball. The cotton ball that was plugged into the mouse mouth was weighed before and after saliva collection. The amount of saliva collected was standardized as mg for 10 min.
Histological assessment. Salivary gland tissues were prepared for sectioning using haematoxylin and eosin (H&E) staining. The size and degree of lymphocyte infiltration in the salivary gland tissues were used to estimate the severity of tissue damage based on a widely used scoring system in which a lymphocytic focus was defined as a group of >50 lymphocytes per 4 mm 2 for each section of salivary gland tissues. The grade scores were classified as follows: 0 = no lymphocytic infiltration; 1 = slight lymphocytic infiltration; 2 = moderate lymphocytic infiltration but less than one lymphocytic focus per 4 mm 2 ; 3 = one lymphocytic focus per 4 mm 2 ; and 4 = more than one lymphocytic focus per 4 mm 2 [27] .
Immunofluorescence staining. For confocal laser scanning microscopy (Leica SP8), sections of mouse salivary gland tissues were stained with monoclonal antibodies against CD4 and either monoclonal antibodies against IFN-c or monoclonal antibodies against IL-4, respectively. Moreover, sections were stained with both Alexa Fluor 488 goat antimouse IgG and Alexa Fluor 594 goat anti-rabbit IgG, while nuclei were counterstained with DAPI. Micrographs were analysed using ImageJ software.
Thymocyte and splenocyte viability measurements. The thymus and spleen were collected in the third week after treatment. Thymocytes and splenocytes were isolated by grinding respective tissue on a sterile 200-mesh strainer and washing the resulting single-cell suspension in ice-cold phosphate-buffered saline (PBS). The cells were suspended in RPMI-1640 medium at a cellular density of 1 9 10 7 cells/ml. Fifty microlitres of thymocytes and 50 ll of Con A or 50 ll of splenocytes and 50 ll of LPS were seeded into 96-well flat-bottomed culture plates. The culture plates were incubated in a 37°C incubator for 48 hr. To determine the viability of the cells, ten microlitres of CCK- 8 were added to each well 4 hr before the end of the culture and incubated at 37°C for an additional 4 hr. The absorbance (A) was measured for each 96-well plate using a Thermo Scientific Multiskan GO at 450 nm.
For detecting the toxicity of CP-25, the viability of spleen cells and fibroblast-like synoviocytes (FLS) was assayed. Splenocytes from ICR mice and FLS from rats were seeded into 96-well plates in octuplicate. CP-25 was added at the final concentrations of 0 (as control), 1 9 10 À5 , 1 9 10 À6 , 1 9 10 À7 , 1 9 10 À8 and 1 9 10 À9 mol/l, respectively. Toxicity of CP-25 in spleen cells and FLS was measured for 48 hr by the MTT method, as described previously [28] . The following formula was used to calculate the cell viability (CV): CV (%) = the experimental group A 490 nm value/control group A 490 nm value 9 100%.
Flow cytometry. Single-cell suspensions of thymocytes were prepared in RPMI-1640 medium at a cellular density of 1 9 10 6 cells/ml and then seeded into 24-well flat-bottomed culture plates. The cultures were incubated in a 37°C incubator for 6 hr, while the cells were stimulated with PMA (BD). They were then stained with fluorescenceconjugated monoclonal antibodies against CD4 and then anti-IL-17 or anti-CD25 and anti-FoxP3 antibodies by intracellular staining. Stained cells were analysed by flow cytometry using FlowJo software version 10.1 (Tree Star Inc., Ashland, OR, USA). Histograms were representative examples and bar graphs were all data collected in flow cytometry figures.
Cytokine measurements. Murine sera were obtained from peripheral blood which was collected from the retro-orbital plexus of treated mice. The concentrations of IL-4, IL-6, IFN-c, TNF-a and IL-17A were measured using CBA Mouse Th1/Th2/Th17 Cytokine Kits according to the manufacturer's instructions. The concentrations of TGF-b1 were measured using ELISA kits according to the manufacturer's instructions.
Measurement of anti-SSA/Ro, anti-SSB/La and IgG antibodies. Murine sera were obtained as described above. The concentrations of anti-SSA/Ro, anti-SSB/La and IgG antibodies were measured using ELISA kits according to the manufacturer's instructions.
Statistical analysis. All data are presented as mean AE S.E.M. We compared the groups with one-way ANOVA, Mann-Whitney or Dunnett's multiple comparisons tests, as appropriate. All analyses were performed using GraphPad Prism 5.0 software (GraphPad Software, Inc., San Diego, CA, USA) or SPSS 16.0. Values of p < 0.05 were considered statistically significant.
Results

CP-25 alleviates clinical manifestations of ESS in NOD/Ltj mice.
The clinical signs of ESS developed rapidly in NOD/Ltj mice after 14 weeks. NOD/Ltj mouse hair was fluffy and colourless, and mice demonstrated continued licking of the lips. CP-25 treatment alleviated the clinical manifestations observed in the NOD/Ltj mice. Compared with the normal group, the NOD/Ltj mice lost weight at the same age. There is little difference in body-weight in NOD/Ltj mice prior to drug administration. Mice treated with different doses of CP-25 gained weight at a similar rate. However, the HCQ treatment group lost significant weight ( fig. 2A) . HCQ-treated mice showed obvious signs of hair loss and a lack of movement. As shown in fig. 2B , the spleen index is not useful, as it is not different in the model compared with normal mice. The thymus indexes in mice in the model group were noticeably lower than those in mice in the normal group. However, there were no significant differences between the model group and drug-treated groups regarding the thymus indexes. By contrast, the salivary gland indexes in mice in the model group were significantly higher than those in mice in the normal group. When mice were treated for two weeks, the salivary gland indexes decreased in the CP-25 (70 mg/kg) and HCQ treatment groups compared with the untreated control group (p < 0.05) ( fig. 2B ).
CP-25 treatment ameliorates the functionality of the salivary glands in NOD/Ltj mice. Histological evaluation of the salivary glands at the 17th week showed noticeable differences between CP-25-treated animals and the untreated control group. NOD/Ltj mice developed noticeable tissue destruction with lymphocytic infiltration in the salivary glands. In comparison, CP-25 treatment (70 mg/kg) attenuated the lymphocytic infiltration in the salivary gland, as did HCQ treatment (80 mg/kg) ( fig. 3A ). Using a previously described scoring system, we quantified the number of lymphocytic foci and found significantly decreased histological scores in the salivary glands of mice that were treated with CP-25 (70 mg/kg) and HCQ (80 mg/kg) ( fig. 3B ). The salivary flow of NOD/Ltj mice was decreased significantly compared to normal controls by the 14th week. Compared with fig. 3C ).
CP-25 reduces lymphocyte viability in NOD/Ltj mice. Because T and B cells are important for the progression of pSS, we determined whether the improvement in CP-25-treated mice was related to the reduction of lymphocyte viability. We collected the thymuses and spleens of mice at the end of the experiment (the 17th week) and tested the viability of the respective cells. As illustrated in fig. 4 , we found increased thymocyte viability after Con A activation and splenocyte viability after LPS activation in NOD/Ltj mice compared with cells isolated from an untreated control group. We also found that CP-25 reduced the viability of T and B cells. CP-25 (35 and 70 mg/kg) and HCQ treatments similarly inhibited T cell viability (p < 0.05). Both CP-25 (70 mg/kg) and HCQ treatments showed similar inhibition of B cell viability (p < 0.01). These results demonstrate that CP-25 can block T and B cell viability ( fig. 4A,B) .
CP-25 has little effect on normal spleen cells and FLS viability in vitro.
The cytotoxicities of CP-25 towards normal spleen cells and FLS were investigated by MTT assay. Our study showed that CP-25 exhibited little or no cytotoxicity towards spleen cells and FLS. The effect on normal spleen cells and FLS viability in vitro was at almost the same level for the different doses of CP-25 ( fig. 5A,B) .
CP-25 suppresses the Th17/IL-17 response in NOD/Ltj mice.
It has been clearly demonstrated that Th17 cells play a critical role in human pSS and in ESS animal models [10, 11] . We therefore examined the percentage of defined Th17 cell subsets in the spleens of NOD/Ltj mice via flow cytometry. We found that both CP-25 (70 mg/kg) and HCQ treatments inhibited IL-17 production by splenocytes from the time of treatment in NOD/Ltj mice. These results showed that the percentage of Th17 cells was significantly decreased from an average of 2.68% in the model mice to 1.75% in the CP-25-treated NOD/Ltj mice ( fig. 6A,B) . The effects of HCQ treatment show significant inhibition of the production of IL-17 (p < 0.01). 
CP-25 increases the percentage of Treg cells in NOD/
CP-25 modulates the level of serum immune-inflammatory cytokines in NOD/Ltj mice.
The serum concentrations of the inflammatory cytokines IFNc, IL-4, IL-6 and IL-17A were significantly increased in NOD/Ltj mice, and the amount of the immunosuppressive cytokine TGF-b1 was decreased, highlighting the dysregulation of these cytokines. After treatment of the NOD/Ltj mice, we found that CP-25 (70 mg/kg) strongly inhibited the amount of the inflammatory cytokines IFN-c, IL-4, IL-6 and IL-17A, and HCQ treatment also decreased the titre of inflammatory cytokines IL-6, IFN-c and IL-17A. However, there were no significant differences between the model group and drug-treated groups in the level of TGF-b1 ( fig. 9C ). In addition, we could show that a lower concentration of CP-25 (35 mg/kg) also was able to inhibit the presence of IL-17A ( fig. 9A,B) .
CP-25 decreases anti-SSB/La and IgG antibodies in NOD/Ltj mice.
The clinical manifestation of pSS is characterized by the presence of autoantibodies. Autoantibodies in patients with pSS and ESS animal models have been reviewed exhaustively and include anti-SSA/Ro, anti-SSB/La and others [29, 30] . The presence of specific antibodies, such as anti-SSA/Ro, anti-SSB/La and IgG, supports the diagnosis and treatment of pSS [30] . Our study showed that the anti-SSA/Ro, anti-SSB/La and IgG antibody levels increased significantly in untreated NOD/Ltj mice. The anti-SSB/La level was decreased significantly in NOD/Ltj mice after treatment with CP-25 (17.5, 35 and 70 mg/kg) and HCQ. In addition, CP-25 (70 mg/kg) and HCQ treatments similarly decreased the concentrations of IgG. However, there were no marked differences between mice in the untreated control group and drug-treated groups regarding the concentrations of anti-SSA/Ro ( fig. 10A-C) .
Discussion
Our study has confirmed that modified glycoside CP-25, which is a new ester derivative of Pae, can be used orally and can overcome the low bioavailability and absorption of Pae in vivo [23, 24] . CP-25 has been reported to have therapeutic effects in rats with AA that are consistent with reductions in immune inflammation and bone damage by reducing inflammatory mediators and modulating immune responses [32] . Previous studies have suggested that CP-25 can regulate dendritic cell (DC) function and inhibit DC maturation in vitro, which could be relevant for the regulatory effects of CP-25 on the PGE2 and TNF-a signalling pathways [33] . In the present study, we demonstrated for the first time that CP-25 is a novel ester derivative of Pae that has therapeutic effects in a model of SSlike diseases in NOD/Ltj mice. We found that treatment with CP-25 improved salivary gland function and regulated immune responses by modulating T lymphocyte subsets that contribute to the progression of pSS symptoms in NOD/Ltj mice. It is well known that in pSS, the salivary glands are functionally impaired because of lymphocyte infiltration and subsequent tissue destruction, which leads to a decrease in the exocrine function of these glands. NOD/Ltj mice are derived from a cataract-prone strain of outbred Jcl/ICR mice and have been widely used as a model of pSS [25] . This mouse model has also been used as a model of type I diabetes, but additionally, mice spontaneously develop lymphocytic infiltration in specific organs, such as the salivary and lacrimal glands, that is more similar to human beings with pSS than has been seen in any other animal model [26] . With onset of pSS-like disease, lymphocyte infiltration in the salivary glands and a decline in salivary flow in NOD/Ltj mice began between 8 and 12 weeks of age [34] . Therefore, we used NOD/Ltj mice as a model of pSS to study disease progression from the age of 8-17 weeks. Our studies have demonstrated that several factors, including the results of a histological assessment, salivary flow and antibody levels (IgG, especially anti-SSA/Ro and anti-SSB/La, both also regarded as useful diagnostic markers of pSS), are present in the NOD/Ltj mice. Analyses of disease development based on the salivary flow and histological scores showed that CP-25 treatment significantly alleviated disease progression with increased salivary flow and improved histological assessment. Additionally, the anti-SSB/La level was decreased significantly after treatment with CP-25. The SSA/Ro and SSB/La autoantibody levels might be associated with salivary gland destruction due to lymphocytic aggregation in glandular structures and an unspecific activation of the immune response [35] . It was reported that serum IgG levels were significantly higher in patients with pSS [36] . Our study demonstrated that CP-25 effectively decreased the concentrations of IgG in NOD/Ltj mice. HCQ treatment resulted in effects that were as significant as those of the CP-25 treatment. However, HCQ made the physical condition of NOD/Ltj mice worse causing off-target effects such as weight loss, hair loss and lack of movement which was not observed in CP-25-treated mice. In contrast, CP-25 not only inhibited the progression of pSS but also improved the physical condition of NOD/Ltj mice. We also found that CP-25 can profoundly reduce lymphocyte viability in NOD/Ltj mice and has few non-specific toxic effects on normal spleen cells and FLS viability in vitro. Th17 cells secrete IL-17, which constitutes a family of cytokines that includes six members, from A to F, with a wide range of biological activities [37] . Recent studies have demonstrated the involvement of IL-17 in autoimmune inflammation during the pathogenesis of pSS [38] and have revealed elevated levels of IL-17A in body fluids from patients with pSS, including tears, saliva and serum [11, [39] [40] [41] [42] . An analysis of mouse models showed that IL-17-deficient mice were completely resistant to ESS induction, and adoptive transfer of Th17 cells drove the development of ESS in IL-17 KO mice [10] . In this study, we determined the percentages of Th17 cells in the periphery and spleens of NOD/Ltj mice. Our results indicated that CP-25 could effectively decrease the percentage of Th17 cells in vitro. These findings provide a possible mechanism by which CP-25 can inhibit in vivo disease progression through suppression of Th17 cells.
Treg cells, expressing biomarkers CD4 + CD25 + FOXP3
+ on their surface, are thought to play a critical role in the development of pSS [13, 14] . However, the role of Treg cells in pSS pathogenesis is controversial, with observations of both a decreased [13, 43, 44] and an increased number of cells, respectively [14, 45] . [46] . These T cell subtypes were described as mutually inhibitory. Th1 cells are characterized by the secretion of IL-2, TNF-a and IFN-c and preferentially induce cellmediated immunity, whereas Th2 cells are characterized by the secretion of IL-4, IL-6, IL-10 and IL-13 and primarily support antibody production, which has all been associated with the extent of lymphocytic infiltration in the salivary glands in pSS [47] [48] [49] [50] . In particular, IL-4 plays an integral role in the development and onset of SS-like disease in the NOD/Ltj mouse model. On the one hand, IL-4 activity may regulate the survival of autoreactive B cells and, indirectly, the degree of lymphocyte infiltration into the salivary and lacrimal glands; on the other hand, it seems to permit the production of IgG1 anti-M3R autoantibodies to promote exocrine gland dysfunction [51] . Previous studies in NOD.IL-4 À/À mice, NOD.IFNc À/À mice and NOD.IFN-cR À/À mice have clearly illustrated the importance of Th1 and Th2 cytokines in the pathogenesis of pSS [52, 53] . Research has suggested that patients with pSS have indeed an altered Th1/Th2 balance [7] [8] [9] . Our study demonstrated that CP-25 decreased the expression of Th1 and Th2 cells in the salivary glands, which improved the histological assessment scores in the salivary glands of NOD/Ltj mice. Additionally, we observed high concentrations of the inflammatory cytokines IFN-c, IL-4 and IL-6 in the sera of NOD/Ltj mice. Our data demonstrated that CP-25 significantly reduced the serum levels of the cytokines IFN-c, IL-4 and IL-6 in NOD/Ltj mice. Th3 cells are regulatory cells and cause immunosuppression through TGF-b production [54] . There are three closely related members in the TGF-b family: TGF-b1, TGF-b2 and TGF-b3. TGF-b1 is considered the primary mediator of inflammatory and immune events. Previous studies in TGFb1 À/À mice indicate that the absence of this cytokine is related to unregulated T cell cytokine proliferation and evolution of an autoimmune-like disorder [56] . Our results show that the amount of the immunosuppressive cytokine TGF-b1 is decreased in NOD/Ltj mice. However, there are no significant differences between the model group and drug-treated groups in the level of TGF-b1. Furthermore, there are other T helper subsets such as Th9, Th22 and TFH which play important roles in some autoimmune diseases [54, 55] . Further studies are required to explore that these subsets could be implicated in pSS and also may be the target of the immunomodulatory action of CP-25.
In conclusion, our study shows for the first time that CP-25 is a novel compound that may be a potent therapeutic agent for pSS, and we hypothesize that CP-25 plays a key role in inhibiting pSS pathogenesis by modulating T lymphocyte subsets. Future studies will validate the use of CP-25 as a therapeutic strategy for the treatment of pSS, as well as for other autoimmune disorders.
